Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. (Nasdaq: FBLG) is a clinical-stage biotechnology company based in Houston that focuses on developing fibroblast-based therapies and fibroblast-derived materials for chronic diseases. News about FibroBiologics often centers on progress in its pipeline, intellectual property developments, and financing activities that support its research and clinical plans.
Company updates include announcements on preclinical and clinical milestones, such as HREC approval in Australia for a Phase 1/2 trial of CYWC628 in diabetic foot ulcers and the filing of a Phase 1/2 IND application with the U.S. FDA for CYPS317 in moderate to severe psoriasis. FibroBiologics also reports preclinical data for programs like CYMS101 for multiple sclerosis and FSdC spheroid therapies for degenerative disc disease, as well as work in bone marrow organoids for cancer and human longevity applications.
Investors following FBLG news will also see coverage of patent filings and intellectual property expansions, including a U.S. patent application for fibroblast-derived spheroids for cartilage and joint repair, and disclosures about the company’s portfolio of more than 270 issued and pending patents. Capital markets news features registered direct offerings, concurrent private placement warrants, and the use of a Standby Equity Purchase Agreement, along with updates on the payoff of outstanding convertible debt.
This news feed aggregates these types of developments in one place, from clinical and scientific updates to proxy statements, Nasdaq compliance notices, and financing transactions. Readers can use it to monitor FibroBiologics’ progress across its fibroblast-based platforms and to track regulatory, corporate, and capital markets events that may affect the FBLG stock.
FibroBiologics (NASDAQ: FBLG) reported Q3 2024 financial results and corporate updates. The company plans to initiate a Phase 1/2 clinical trial for its CYWC628 product to treat diabetic foot ulcers in Q2 2025. For the nine months ended September 30, 2024, R&D expenses increased to $3.1M from $1.6M, and G&A expenses rose to $6.9M from $4.8M year-over-year. Net loss widened to $8.1M compared to $6.8M in the same period of 2023. Cash position stood at $7.8M as of September 30, 2024. The company expanded its IP portfolio with multiple patent issuances and joined the Russell 2000® Index.
FibroBiologics (Nasdaq: FBLG) reported promising results from its artificial thymus organoid program. The technology demonstrated that fibroblasts and thymus-derived cell organoids can maintain functionality for over 50 days after transplantation, showing vascularization and generating diverse mature T cells in animal models. The organoids produced fully mature T cells with various differentiation capabilities, including CD4, CD8, T-regulatory, and gamma delta T cells. The artificial thymus also generates T cells with diverse TCR-beta chains for broad antigen recognition, potentially supporting immune function in patients with immune dysregulation or post-chemotherapy conditions.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with 160+ patents, announced upcoming presentations at two major conferences. The company will present at the 2024 ThinkEquity Conference in New York on October 30, 2024, at 10:30 a.m. ET, and at BIO-Europe 2024 in Stockholm on November 5, 2024, at 1:30 p.m. CET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. Their patent portfolio covers various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics (Nasdaq: FBLG) and Charles River Laboratories have established a master services agreement to develop and manufacture FibroBiologics' therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for a diabetic foot ulcer (DFU) clinical trial planned for 2025. The collaboration aims to leverage Charles River's expertise in cell and gene therapy manufacturing to support FibroBiologics' innovative fibroblast-based therapies for chronic diseases.
Key points:
- Technology transfer and feasibility studies have been successfully completed
- Charles River will serve as the contract development and manufacturing organization (CDMO) for FibroBiologics' clinical trial drug products
- The partnership is expected to accelerate progress in delivering fibroblast-based treatments to patients
- FibroBiologics is investigating fibroblasts and fibroblast-derived materials for multiple indications, including wound healing, multiple sclerosis, and cancer
FibroBiologics (Nasdaq: FBLG) has been granted a patent by the European Patent Office for a novel cancer treatment method using modified fibroblasts to deliver anti-cancer agents. The patent (Number 19795975.2) covers methods and compositions for enhancing fibroblasts' ability to target cancerous tissues and deliver tumor-inhibiting agents directly to cancer cells.
This innovative approach aims to improve the effectiveness of cancer treatments by leveraging fibroblasts' natural ability to penetrate tumor tissues and modulate immune responses. The technology could potentially address challenges faced by traditional therapies, such as tumor penetration, and may offer new possibilities for treating primary, metastatic, and treatment-resistant tumors.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Pete O'Heeron will engage in a fireside chat on October 16, 2024, at 10:00 a.m. ET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Based in Houston, FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, interested parties can visit the company's website or contact them directly via email.
FibroBiologics (Nasdaq: FBLG) announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2024 Cell & Gene Meeting on the Mesa Conference in Phoenix, Arizona, on October 7, 2024. The presentation will focus on updates regarding the company's pre-clinical IND-enabling studies in chronic wound healing and psoriasis, as they prepare for a phase I/II diabetic foot ulcer (DFU) clinical trial with their CYWC628 topically administered fibroblast spheroid product candidate.
Dr. Khoja emphasized the company's approach of leveraging the regenerative potential of fibroblasts for tissue repair and immune modulation. FibroBiologics aims to create innovative cell-based approaches for treating chronic diseases. The presentation is scheduled for 5:45 p.m. MST in the FLW Ballroom F.
FibroBiologics (Nasdaq: FBLG) has engaged Southern Star Research as its CRO in Australia to prepare for a Phase 1/2 clinical trial of CYWC628, a treatment for diabetic foot ulcers. This partnership aims to leverage Australia's high-quality clinical trial infrastructure and R&D incentives. CYWC628 is an allogeneic fibroblast cell-based therapy designed to promote wound healing, particularly for difficult-to-treat diabetic foot ulcers.
CEO Pete O'Heeron stated that this engagement is important for establishing FibroBiologics' clinical trial infrastructure in Australia. The company, with 160+ patents issued and pending, focuses on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials.
FibroBiologics (Nasdaq: FBLG) has filed a patent application for generating three-dimensional hemopoietic organoids using fibroblast cell-based technology. This method could potentially produce therapeutic organoids capable of giving rise to various immune cells, including T cells, B cells, NK cells, and CAR-T cells. The process is described as rapid, cost-effective, and scalable, with organoids ready for transplantation within three days or cryopreserved for later use.
Dr. Hamid Khoja, Chief Scientific Officer, highlighted the potential for these organoids to be transplanted into living organisms to generate functional immune cells. CEO Pete O'Heeron emphasized that this patent, if issued, could allow FibroBiologics to develop a versatile solution for in vivo immune cell generation, potentially revolutionizing regenerative medicine and cancer immunotherapy.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. Pete O'Heeron, Founder and CEO, will represent the company.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents. Their presentation will be available on-demand to registered attendees starting September 9, 2024, at 7 a.m. Eastern Time.
Interested parties can find more information on FibroBiologics' website or by contacting info@fibrobiologics.com.